GlobeNewswire by notified

Axi launches Axi Select, a pioneering all-inclusive capital allocation programme offering skilled traders funding of up to $1,000,000 USD

Share

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

[We see the Trader in You !]

SYDNEY, Australia, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Axi a leading global Forex and CFD broker has announced the launch of Axi Select, a groundbreaking capital allocation programme. The programme is specifically crafted to empower traders by offering them a pathway to access capital funding up to$1,000,000 USD and facilitating their progression into professional trading. Setting a new precedent within the industry, Axi Select offers traders the exceptional advantage to join the program with zero registration fees, as well as the opportunity to earn up to 90% of their profits.

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.Greg Rubin, Head of Axi Select, says: “Through the introduction of Axi Select, our innovative capital allocation programme, we aim to provide an opportunity for traders to forge long and successful careers, empowering them to realize their lifelong aspirations of becoming professional traders. Our comprehensive programme provides the capital, support, and resources necessary for traders to thrive in the dynamic world of trading. We are committed to fuelling their passion, driving their success, and providing unwavering support as they navigate towards achieving their goals.” The programme offers a range of notable features, including unrestricted trading conditions, the Edge score which allows traders to fine-tune their strategies and enhance their trading performance, and an exclusive trading room which serves as a dedicated hub, offering real-time market updates and curated educational content. 

[LEARN MORE AND JOIN AXI SELECT]

The Axi Select programme is only available to clients of AxiTrader Limited. CFDs carry a high risk of investment loss. This content is not available for AU, NZ, and UK clients. For more information, refer to our Terms of Service. Other Fees may apply.

Click here to watch the Axi Select fireside chat

Talking about Axi Select, Louis Cooper, Chief Commercial Officer at Axi, says “At Axi, we take pride in being a brand that consistently brings the edge to life for our customers. Our revolutionary new offering, Axi Select, is the first-of-its-kind among brokers and another true reflection of our brand promise. We have previously allocated $39M to traders in previous programmes and enabled several traders break out into pro trading status. With Axi Select, we will deliver unparalleled opportunities to our traders whilst both redefining the boundaries of what’s possible in trading and reshaping the evolution of the financial industry.”

Axi offers a streamlined process to participate in Axi Select – with no signup or membership fees, traders can effortlessly submit their application and start trading. Upon achieving a designated Edge Score, traders can start to secure capital funding of up to $1,000,000 USD.

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

[LEARN MORE AND JOIN AXI SELECT]


The Axi Select programme is only available to clients of AxiTrader Limited. CFDs carry a high risk of investment loss. This content is not available for AU, NZ, and UK clients. For more information, refer to our Terms of Service. Other Fees may apply.

Click here to watch the Axi Select fireside chat

About Axi

Axi is a global online FX and CFD trading company, trusted by thousands of ambitious customers in 100+ countries around the world. We help all types of traders, trading businesses, banks and financial organizations find the edge they need to achieve their financial goals through informed transactions made on the world's financial markets. Axi offers a wide range of assets including CFDs for several asset classes including Forex, Shares, Gold, Silver, Oil, Coffee, Indices, and other commodities.

At Axi, we are proud of our reputation as an honest, fair, and trusted broker. Our many awards and 'Great' Trustpilot reviews prove we have earned the confidence of customers who value our outstanding service, fast execution, secure payments, segregated funds, and easy withdrawals.

For further enquiries contact service@axi.com

Check out other Axi communication at https://www.axi.com/int/blog/company-news

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d50c2d41-8931-47bd-9b0f-6a5572fb88e4
https://www.globenewswire.com/NewsRoom/AttachmentNg/987d1f0e-63e9-4234-aaaf-6c041d74d3ba
https://www.globenewswire.com/NewsRoom/AttachmentNg/9a391ff3-5046-485a-916e-cca5bbb247b2

PDF accompanying this announcement is available at: 
http://ml-eu.globenewswire.com/Resource/Download/1cfa04fb-a4cb-4b4d-b0dc-5b14a9f0aa0f

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration3.10.2023 22:05:00 CEST | Press release

PHAXIAM Therapeutics and Vetophage Announce Strategic ResearchCollaboration Strategic research partnership between PHAXIAM Therapeutics and Vetophage, a biotechnology company specialized in veterinary phage therapy Combining expertise in the research of new phages and phage endolysins that could be applied to human health Exclusive phage and endolysin licensing options in human health for PHAXIAM Therapeutics Lyon (France) and Cambridge (MA, US), October03, 2023 – 10:05pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) and Vetophage, a company specialized in phage therapy applied to animal health, announce the signature of a long-term strategic research partnership to combine their expertise in the research of new phages and phage-derived proteins (endolysins) in the fight against antimicrobial resistance. Vetophage is a Lyon-based biotechnology company founded in 2017. It develops new tools to detect pathogenic bacteria and alternative solutions to antibiotics based on phages an

Kvika banki hf.: TM Insurance to be sold or listed3.10.2023 21:05:43 CEST | Press release

Following a strategic review at Kvika banki hf. ("Kvika" or "the bank"), the board of directors of Kvika has decided to initiate a process for the sale or listing of its insurance subsidiary TM tryggingar hf. ("TM"). The decision is in line with the bank's vision, where emphasis is placed on simplifying the group's operations and strengthening Kvika's traditional banking activities, in accordance with the bank's goal to increase competition and simplify its customers' finances. Following the divestment of TM, Kvika's main operations will be focused on commercial- and investment banking, along with asset management. It is expected that Kvika's capital base will grow significantly following the divestment of TM, enabling the bank to pursue internal growth opportunities across Kvika's business segments. Increased capital will, among other things, enable the bank to strengthen its market position, in both retail and corporate lending, and increase the risk diversification of its loan book.

Policane® Natural Sweetener Found to Have Low Glycemic Index3.10.2023 20:06:38 CEST | Press release

OCALA, Fla., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Policane®, a natural sweetener made from sugar cane juice in a patented process, has been found to have a low glycemic index (GI) in a study by IFP Suisse SA. According to the study Policane® has a GI of 51.7+/- 3.66. The study also found that Policane® had a 42% lower GI than white sugar. In its conclusion, the study recommends for Policane® a low glycaemic index product classification under International Standard ISO26642. “We are excited to share the results of this study, providing that Policane® is a low-GI sweetener,” said Jorge Enrique Gonzalez, Manager and CEO at PoliCane Co., LLC. “Policane® retains the best parts of the sugar cane stripped away in refined sugar. Policane® is a natural and sustainable sweetener that the world needs.” Policane® is currently produced under license in Costa Rica and can be used in recipes for all sweetened food and beverages, including baked goods, coffee, tea, colas, sauces, ketchup and desserts. Fo

Nokia Corporation: Repurchase of own shares on 03.10.20233.10.2023 20:00:00 CEST | Press release

Nokia Corporation Stock Exchange Release 3 October 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 03.10.2023 Espoo, Finland – On 3 October 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL344,5423.53CEUX39,5413.54AQEU1,3923.53TQEX14,5253.55Total400,0003.53 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023

Adevinta ASA – Procedures established in response to receipt of non-binding indicative proposal3.10.2023 19:30:00 CEST | Press release

Oslo, 3 October 2023 – Adevinta ASA (“Adevinta” or the “Company”) refers to the stock exchange announcement on 21 September 2023 regarding receipt of a non-binding indicative proposal (the “Proposal”) from a consortium led by Permira and Blackstone, with involvement of the Company’s two main shareholders, regarding a potential offer for all shares of the Company. In response to shareholder enquiries, the Company wants to communicate the procedures it is following in response to the Proposal. Immediately upon receipt of the Proposal, the Company’s board of directors established a special committee comprising the five independent directors on the Company’s board. The special committee is representing the Company in all aspects relating to the Proposal. The directors who are representatives of the three main shareholders of the Company are not involved in the Company’s deliberations and decisions. The independent committee is actively engaging in the Proposal in line with applicable regul